Company Overview and News

 
UNSW signs deal to go fully solar powered

2018-01-14 theage.com.au
UNSW has signed a 15-year agreement with solar company Maoneng Australia and energy company Origin for a solar corporate power purchase agreement (PPA).

 
UNSW signs deal to go fully solar powered

2018-01-14 smh.com.au
UNSW has signed a 15-year agreement with solar company Maoneng Australia and energy company Origin for a solar corporate power purchase agreement (PPA).

 
AGL goes green at Liddell, but prices remain high

2017-12-11 theage.com.au
AGL's shutdown of the Liddell coal-fired power station is a win for renewable energy and lower emissions, but don't expect a steep fall in prices.

 
AGL goes green at Liddell, but prices remain high

2017-12-11 smh.com.au
AGL's shutdown of the Liddell coal-fired power station is a win for renewable energy and lower emissions, but don't expect a steep fall in prices.

 
2018 tipped to be SA's toughest energy year yet

2017-12-07 theage.com.au
South Australia's energy prices may have reached record highs this year, but analysts expect next year to be even worse for the state.

 
2018 tipped to be SA's toughest energy year yet

2017-12-07 smh.com.au
South Australia's energy prices may have reached record highs this year, but analysts expect next year to be even worse for the state.

 
Businesses face electricity contract renewal 'cliff'

2017-11-13 theage.com.au
The combination of higher energy prices, tighter credit controls, hot summers and contract renewals are creating a perfect storm for industrial energy users, energy brokers say.

 
Businesses face electricity contract renewal 'cliff'

2017-11-13 smh.com.au
The combination of higher energy prices, tighter credit controls, hot summers and contract renewals are creating a perfect storm for industrial energy users, energy brokers say.

 
Ross Garnaut says WA could be energy superpower

2017-11-07 theage.com.au
Western Australia's abundance of resources and isolation from the rest of the nation means it is ideally positioned to be an energy superpower, economist Professor Ross Garnaut says.

 
Ross Garnaut says WA could be energy superpower

2017-11-07 smh.com.au
Western Australia's abundance of resources and isolation from the rest of the nation means it is ideally positioned to be an energy superpower, economist Professor Ross Garnaut says.

 
NEG's ability to cut energy costs divides analysts

2017-11-05 theage.com.au
As the energy prices continue to rise, analysts are mixed over whether the federal government's National Energy Guarantee can halt the upward march of costs.

 
NEG's ability to cut energy costs divides analysts

2017-11-05 smh.com.au
As the energy prices continue to rise, analysts are mixed over whether the federal government's National Energy Guarantee can halt the upward march of costs.

 
ACT power and gas price rises hitting Canberra business bottom lines

2017-07-07 theage.com.au
Canberra businesses are hunting for ways to keep electricity costs down as they brace for the impact of power price hikes. 

 
ACT power and gas price rises hitting Canberra business bottom lines

2017-07-07 smh.com.au
Canberra businesses are hunting for ways to keep electricity costs down as they brace for the impact of power price hikes. 

 
Finkel puts energy security centre stage - but what about the cost?

2017-06-09 smh.com.au
After widespread power blackouts last summer, the long-awaited Finkel review of the electricity market has put energy security and stability centre stage, with a raft of technical recommendations put to the Council of Australian Governments meeting on Friday. But tackling the more complex issue of how to move beyond the existing renewable energy target remains on the backburner.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...